Open letter to Reata and the FDA – Ataxia

Open letter to Reata and the FDA

Open letter to Reata and the FDA

FARA’s campaign asks people affected by Friedreich’s ataxia to sign their open letter. The letter addresses the US regulator, FDA, and Reata pharmaceuticals. The letter requests Reata to submit a new drug application. It also asks the FDA to consider the approval of a new drug application for Omaveloxolone based on current evidence.
Omaveloxolone is not currently approved for normal clinical use.
Ataxia UK supports FARA’s campaign and has written a supporting letter to the FDA and Reata. Click here to read our letter.
UPDATE: The date for signing the letter has now passed, but if you are interested in knowing more visit:


Something went wrong. Please check your entries and try again.
fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top